S&P 500 jumps as AMD rally leads tech higher
SAN DIEGO - Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), whose stock has surged over 40% in the past six months according to InvestingPro data, has secured seven new patents in Europe, Germany, Taiwan, and China for its AI Nose digital olfaction platform, the company announced Tuesday.
The new patents bring Ainos’s total to 123 active patents across the U.S., Europe, Germany, Japan, Taiwan, and China, covering product design, internal structures, system configurations, and operating principles of its scent digitization technology. With a market capitalization of $16.6 million, the company trades at 1.45 times book value.
The AI Nose platform is designed to convert scent into digital data using MEMS sensor arrays and AI algorithms, with applications across multiple industries. The technology aims to provide real-time scent detection for healthcare settings, anomaly detection in semiconductor manufacturing, and sensory capabilities for robotics and automated production lines.
"AI Nose digitizes smell, the critical human sense that has been absent from machines-until now," said Eddy Tsai, Chairman, President, and CEO of Ainos, according to the press release.
The company stated it is pursuing a SmellTech-as-a-Service business model and remains on track for its planned 2026 commercialization timeline. Ainos has filed additional patent applications in major markets to further expand its intellectual property portfolio. InvestingPro analysis indicates the company is quickly burning through cash, with a current ratio of 2.88 suggesting adequate short-term liquidity.
Ainos describes its technology as capable of detecting scent at parts-per-billion sensitivity and converting analog scent data into actionable insights through a proprietary smell language model that learns complex scent patterns.
The company’s dual focus includes both AI-powered scent technology and immune therapeutics, including VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Despite significant revenue growth of 70% in the last twelve months, InvestingPro data reveals the company remains unprofitable, with analysts anticipating sales challenges ahead. Get access to 8 additional exclusive ProTips and comprehensive financial analysis with InvestingPro.
In other recent news, Ainos, Inc. has filed a prospectus supplement with the Securities and Exchange Commission to offer and sell up to $874,496 of additional common stock through an at-the-market offering agreement with H.C. Wainwright & Co., LLC. This move follows a previous increase in the aggregate offering price to $1,840,350, with the company having sold approximately $1,840,337 of common stock under the agreement. Ainos has also secured a significant three-year subscription-based order valued at $2.1 million with ASE Technology Holding Co., Ltd., marking the first commercial application of its AI Nose platform in semiconductor manufacturing. This agreement will see the deployment of 1,400 AI Nose units across ASE’s manufacturing sites in Taiwan. Additionally, Ainos announced plans to deploy robots equipped with AI Nose technology at seven industrial sites across Japan, in partnership with ugo, Inc. This deployment will cover sectors such as pharmaceutical manufacturing and energy operations. The company also completed a 1-for-5 stock consolidation to strengthen its capital structure and meet Nasdaq listing requirements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.